AZN
阿斯特捷利康 ADR ASTRAZENECA PLC
+2.84 (+1.74%)165.73USD1.8M成交股數–市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-10-30下次財報
公司文件 SEC EDGAR 申報索引 · 全部連到 SEC 原件 · 本站不存文字
財報新聞稿(8-K Item 2.02 的 EX-99)是 guidance 與 non-GAAP 數字的出處;投資人簡報是法說會投影片;逐字稿是第三方整理的外部連結。
財報季必讀有新聞稿或簡報附件的申報
| 申報日 | 表格 | 附件 |
|---|---|---|
| 沒有分類過的附件。 | ||
法說會逐字稿外部連結索引
| 會計季 | 日期 | 連結 |
|---|---|---|
| FY2020 Q4 | 2021-02-12 | The Motley Fool |
| FY2020 Q3 | 2020-11-05 | The Motley Fool |
| FY2020 Q2 | 2020-07-31 | The Motley Fool |
逐字稿由出版方整理,著作權屬出版方;本站只列出連結,不重製內容。
全部申報 最近 120 筆
| 申報日 | 表格 | 類型 | 期末 | 內容 |
|---|---|---|---|---|
| 2026-09-15 | 6-K | 外國發行人臨時報告 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-15 | 6-K | 外國發行人臨時報告 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-14 | 6-K | 外國發行人臨時報告 | 2026-09-14 | UPDATE ON SERENA-4 PHASE III TRIAL |
| 2026-09-08 | 6-K | 外國發行人臨時報告 | 2026-09-08 | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER |
| 2026-09-08 | 6-K | 外國發行人臨時報告 | 2026-09-08 | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | DIRECTORATE CHANGE |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | TOTAL VOTING RIGHTS |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY |
| 2026-08-27 | 6-K | 外國發行人臨時報告 | 2026-08-27 | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS |
| 2026-08-25 | 6-K | 外國發行人臨時報告 | 2026-08-25 | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING |
| 2026-08-19 | 6-K | 外國發行人臨時報告 | 2026-08-19 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-17 | 6-K | 外國發行人臨時報告 | 2026-08-17 | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL |
| 2026-08-17 | 6-K | 外國發行人臨時報告 | 2026-08-17 | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER |
| 2026-08-17 | 6-K | 外國發行人臨時報告 | 2026-08-17 | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG |
| 2026-08-03 | 6-K | 外國發行人臨時報告 | 2026-08-03 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 2026-08-03 | 6-K | 外國發行人臨時報告 | 2026-08-03 | TOTAL VOTING RIGHTS |
| 2026-07-31 | 6-K | 外國發行人臨時報告 | 2026-07-31 | DATROWAY APPROVED IN EU FOR TNBC |
| 2026-07-27 | 6-K | 外國發行人臨時報告 | 2026-07-27 | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS |
| 2026-07-27 | 6-K | 外國發行人臨時報告 | 2026-07-27 | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA |
| 2026-07-27 | 6-K | 外國發行人臨時報告 | 2026-06-30 | FORM 6-K |
| 2026-07-23 | 6-K | 外國發行人臨時報告 | 2026-07-23 | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER |
| 2026-07-14 | 6-K | 外國發行人臨時報告 | 2026-07-14 | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR |
| 2026-07-09 | 6-K | 外國發行人臨時報告 | 2026-07-09 | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL |
| 2026-07-01 | 6-K | 外國發行人臨時報告 | 2026-07-01 | TOTAL VOTING RIGHTS |
| 2026-07-01 | 6-K | 外國發行人臨時報告 | 2026-07-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 2026-06-29 | 6-K | 外國發行人臨時報告 | 2026-06-29 | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS |
| 2026-06-29 | 6-K | 外國發行人臨時報告 | 2026-06-29 | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC |
| 2026-06-15 | 6-K | 外國發行人臨時報告 | 2026-06-15 | TRUQAP APPROVED IN US FOR PROSTATE CANCER |
| 2026-06-01 | 6-K | 外國發行人臨時報告 | 2026-06-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 2026-06-01 | 6-K | 外國發行人臨時報告 | 2026-06-01 | TOTAL VOTING RIGHTS |
| 2026-05-29 | 6-K | 外國發行人臨時報告 | 2026-05-29 | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER |
| 2026-05-27 | 6-K | 外國發行人臨時報告 | 2026-05-27 | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED |
| 2026-05-26 | 6-K | 外國發行人臨時報告 | 2026-05-26 | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU |
| 2026-05-26 | 6-K | 外國發行人臨時報告 | 2026-05-26 | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC |
| 2026-05-26 | 6-K | 外國發行人臨時報告 | 2026-05-26 | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS |
| 2026-05-18 | 6-K | 外國發行人臨時報告 | 2026-05-18 | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS |
| 2026-05-18 | 6-K | 外國發行人臨時報告 | 2026-05-18 | BAXFENDY APPROVED IN THE US FOR HYPERTENSION |
| 2026-05-18 | 6-K | 外國發行人臨時報告 | 2026-05-18 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-14 | 6-K | 外國發行人臨時報告 | 2026-05-14 | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER |
| 2026-05-01 | 6-K | 外國發行人臨時報告 | 2026-05-01 | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER |
| 2026-05-01 | 6-K | 外國發行人臨時報告 | 2026-05-01 | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER |
| 2026-05-01 | 6-K | 外國發行人臨時報告 | 2026-05-01 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES |
| 2026-04-29 | 6-K | 外國發行人臨時報告 | 2026-04-29 | 1ST QUARTER RESULTS |
| 2026-04-28 | 6-K | 外國發行人臨時報告 | 2026-04-28 | BREZTRI APPROVED IN THE US FOR ASTHMA |
| 2026-04-27 | 6-K | 外國發行人臨時報告 | 2026-04-27 | SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US |
| 2026-04-23 | 6-K | 外國發行人臨時報告 | 2026-04-23 | DIRECTORATE CHANGE |
| 2026-04-21 | 6-K | 外國發行人臨時報告 | 2026-04-21 | I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT |
| 2026-04-20 | 6-K | 外國發行人臨時報告 | 2026-04-20 | THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD |
| 2026-04-09 | 6-K | 外國發行人臨時報告 | 2026-04-09 | RESULT OF AGM |
| 2026-04-02 | 6-K | 外國發行人臨時報告 | 2026-04-02 | IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER |
| 2026-04-01 | 6-K | 外國發行人臨時報告 | 2026-04-01 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES |
| 2026-03-31 | 6-K | 外國發行人臨時報告 | 2026-03-31 | EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS |
| 2026-03-27 | 6-K | 外國發行人臨時報告 | 2026-03-27 | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS |
| 2026-03-20 | 6-K | 外國發行人臨時報告 | 2026-03-20 | NOTIFICATION OF ADMISSION OF SHARES |
| 2026-03-16 | 6-K | 外國發行人臨時報告 | 2026-03-16 | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER |
| 2026-03-10 | 6-K | 外國發行人臨時報告 | 2026-03-10 | NOTICE OF AGM |
| 2026-03-10 | 6-K | 外國發行人臨時報告 | 2026-03-10 | FORM 6-K |
| 2026-03-06 | 6-K | 外國發行人臨時報告 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-03-06 | 6-K | 外國發行人臨時報告 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-03-06 | 6-K | 外國發行人臨時報告 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-03-02 | 6-K | 外國發行人臨時報告 | 2026-03-02 | TOTAL VOTING RIGHTS |
| 2026-03-02 | 6-K | 外國發行人臨時報告 | 2026-03-02 | FORM 6-K |
| 2026-02-26 | 6-K | 外國發行人臨時報告 | 2026-02-26 | ASTRAZENECA PRICES A $2BN BOND OFFERING |
| 2026-02-25 | 6-K | 外國發行人臨時報告 | 2026-02-25 | FILING OF FORM 20-F WITH SEC |
| 2026-02-24 | 6-K | 外國發行人臨時報告 | 2026-02-24 | DIRECTORATE CHANGE |
| 2026-02-24 | 6-K | 外國發行人臨時報告 | 2026-02-24 | ANNUAL FINANCIAL REPORT |
| 2026-02-24 | 6-K | 外國發行人臨時報告 | 2026-02-24 | FORM 6-K |
| 2026-02-24 | 20-F | 外國發行人年報 | 2025-12-31 | 20-F |
| 2026-02-20 | 6-K | 外國發行人臨時報告 | 2026-02-20 | FIXED-DURATION CALQUENCE COMBO APPROVED IN US |
| 2026-02-10 | 6-K | 外國發行人臨時報告 | 2026-02-10 | FINAL RESULTS |
| 2026-02-03 | 6-K | 外國發行人臨時報告 | 2026-02-03 | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION |
| 2026-02-02 | 6-K | 外國發行人臨時報告 | 2026-02-02 | TOTAL VOTING RIGHTS |
| 2026-02-02 | 6-K | 外國發行人臨時報告 | 2026-02-02 | ASTRAZENECA BEGINS TRADING ON NYSE |
| 2026-02-02 | 6-K | 外國發行人臨時報告 | 2026-02-02 | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER |
| 2026-01-30 | 6-K | 外國發行人臨時報告 | 2026-01-30 | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC |
| 2026-01-29 | 6-K | 外國發行人臨時報告 | 2026-01-29 | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 |
| 2026-01-20 | 6-K | 外國發行人臨時報告 | 2026-01-20 | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE |
| 2026-01-08 | 6-K | 外國發行人臨時報告 | 2026-01-08 | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON |
| 2026-01-02 | 6-K | 外國發行人臨時報告 | 2026-01-02 | TOTAL VOTING RIGHTS |
| 2025-12-22 | 6-K | 外國發行人臨時報告 | 2025-12-22 | DIRECTOR/PDMR SHAREHOLDING |
| 2025-12-22 | 6-K | 外國發行人臨時報告 | 2025-12-22 | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB |
| 2025-12-22 | 6-K | 外國發行人臨時報告 | 2025-12-22 | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC |
| 2025-12-19 | 6-K | 外國發行人臨時報告 | 2025-12-19 | DIRECTOR/PDMR SHAREHOLDING |
| 2025-12-16 | 6-K | 外國發行人臨時報告 | 2025-12-16 | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC |
| 2025-12-16 | 6-K | 外國發行人臨時報告 | 2025-12-16 | SUBCUTANEOUS SAPHNELO APPROVED IN EU |
| 2025-12-04 | 6-K | 外國發行人臨時報告 | 2025-12-04 | HOLDING(S) IN COMPANY |
| 2025-12-01 | 6-K | 外國發行人臨時報告 | 2025-12-01 | TOTAL VOTING RIGHTS |
| 2025-12-01 | 6-K | 外國發行人臨時報告 | 2025-12-01 | BLOCK LISTING INTERIM REVIEW |
| 2025-11-26 | 6-K | 外國發行人臨時報告 | 2025-11-26 | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER |
| 2025-11-24 | 6-K | 外國發行人臨時報告 | 2025-11-24 | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND |
| 2025-11-20 | 6-K | 外國發行人臨時報告 | 2025-11-20 | KOSELUGO (SELUMETINIB) APPROVED IN THE US |
| 2025-11-17 | 6-K | 外國發行人臨時報告 | 2025-11-17 | HOLDING(S) IN COMPANY |
| 2025-11-14 | 6-K | 外國發行人臨時報告 | 2025-11-14 | DIRECTOR/PDMR SHAREHOLDING |
| 2025-11-10 | 6-K | 外國發行人臨時報告 | 2025-11-10 | DIRECTOR/PDMR SHAREHOLDING |
| 2025-11-06 | 6-K | 外國發行人臨時報告 | 2025-11-06 | 9M AND Q3 2025 RESULTS |
| 2025-11-03 | 6-K | 外國發行人臨時報告 | 2025-11-03 | RESULT OF GENERAL MEETING |
| 2025-11-03 | 6-K | 外國發行人臨時報告 | 2025-11-03 | FORM 6-K |
| 2025-11-03 | 6-K | 外國發行人臨時報告 | 2025-11-03 | TOTAL VOTING RIGHTS |
| 2025-10-28 | 6-K | 外國發行人臨時報告 | 2025-10-28 | KOSELUGO (SELUMETINIB) APPROVED IN THE EU |
| 2025-10-28 | 6-K | 外國發行人臨時報告 | 2025-10-28 | DIRECTOR DECLARATION |
| 2025-10-22 | 6-K | 外國發行人臨時報告 | 2025-10-22 | TEZSPIRE APPROVED IN EU FOR CRSWNP |
| 2025-10-20 | 6-K | 外國發行人臨時報告 | 2025-10-20 | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO |
| 2025-10-20 | 6-K | 外國發行人臨時報告 | 2025-10-20 | US FDA APPROVES TEZSPIRE IN CRSWNP |
| 2025-10-14 | 6-K | 外國發行人臨時報告 | 2025-10-14 | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES |
| 2025-10-07 | 6-K | 外國發行人臨時報告 | 2025-10-07 | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL |
| 2025-10-06 | 6-K | 外國發行人臨時報告 | 2025-10-06 | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 |
| 2025-10-01 | 6-K | 外國發行人臨時報告 | 2025-10-01 | TOTAL VOTING RIGHTS |
| 2025-09-29 | 6-K | 外國發行人臨時報告 | 2025-09-29 | 6-K |
| 2025-09-29 | 6-K | 外國發行人臨時報告 | 2025-09-29 | AZN HARMONISES LISTING STRUCTURE |
| 2025-09-29 | 6-K | 外國發行人臨時報告 | 2025-09-29 | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 |
| 2025-09-25 | 6-K | 外國發行人臨時報告 | 2025-09-25 | DIRECTOR/PDMR SHAREHOLDING |
| 2025-09-22 | 6-K | 外國發行人臨時報告 | 2025-09-22 | KOSELUGO RECOMMENDED FOR EU APPROVAL |
| 2025-09-22 | 6-K | 外國發行人臨時報告 | 2025-09-22 | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP |
| 2025-09-17 | 6-K | 外國發行人臨時報告 | 2025-09-17 | UPDATE ON RESOLUTE PHASE III TRIAL |
| 2025-09-17 | 6-K | 外國發行人臨時報告 | 2025-09-17 | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC |
| 2025-09-02 | 6-K | 外國發行人臨時報告 | 2025-09-02 | TOTAL VOTING RIGHTS |